Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

The merger of Accuray and TomoTherapy would combine two of the 11 medical device companies that went public in 2007, a class of companies that has produced mixed results.

Looking back at 2007, the performance of the medical industry seems strong, from blockbuster M&A to a better-than-expected result of a years-long DOJ investigation into the orthopedics industry. Even Boston Scientific seemed finally to be turning the corner. Drug-eluting stents (DES) got a second chance as data presented from several trials showed better mortality than with bare-metal stents. Venture capitalists poured even more money into device start-ups, both young and old. The confidence shown by venture investors was, not surprisingly, reflected in an IPO market that appeared to continue its recent rebound. But there are also some concerns: company consolidation, increased safety concerns and litigation revolving around physician-manufacturer relationships are causing some to wonder how long the foundation on which the industry's strong showing of recent years can sustain.